Safety of OA-SYS for moderate to severe knee osteoarthritis
Tests how safe and tolerable OA-SYS is in people with knee osteoarthritis.
Key facts
- Who runs it
- Ageless Biotech, Inc.
- Where
- Las Vegas, United StatesSee the site
- Trial code
- Registry title
- An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 400 people, planned
- Started
- 21 May 2025
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Treatments tested
- OA-SYS
- Record updated
- 18 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate to severe osteoarthritis (joint wear) of the knee, to test the safety of OA-SYS.
- Age
- 35 to 75 years
- Sex
- All sexes
- Disease stage
- Moderate to severe knee osteoarthritis, Kellgren-Lawrence grade 3 or 4 on X-ray. People must be able to walk, be in good general health and have a BMI less than 39 kg/m2.
- Earlier treatment
- No surgery for osteoarthritis in the knee being studied. No joint injections such as sodium hyaluronate, corticosteroids or biologic agents (e.g. PRP, stem cells) in the 6 months before screening. No immunosuppressants such as cyclosporin A or azathioprine in the 6 weeks before screening.
Main reasons for not taking part
- Infection, recent fracture, instability or metal hardware in the knee being studied
- Rheumatoid arthritis, other inflammatory arthritis or autoimmune disease
- Severe heart disease or high blood pressure not controlled below 140/90 mmHg
- Cancer in the 5 years before screening, mental disorder or epilepsy
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Adults between the ages of 35 - 75 years Body Mass Index (BMI) less than 39 kg/m2
- Ambulatory and in good general health
- Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions
- Willing to abstain from use of protocol-restricted treatments from Screening through End-of-Treatment
- Kellgren-Lawrence grading scale score of 3 or 4 for OA of the knee
- No clinically significant abnormalities observed in medical history, physical exam vital signs, and laboratory assessments
- For females of reproductive potential: use of effective contraception for at least 1 month prior to screening and agreement to use such a method till end of the study period and negative pregnancy test
- For males of reproductive potential: use of condoms and other methods to ensure effective contraception
Who cannot take part
- Subjects with surgery for OA in the target joint
- Subject with myocardial infarction, congestive heart failure, and other severe heart disease or hypertension (or medical history of hypertension) that are not controlled below 140/90 mmHg even with treatment with more than three antihypertensive drugs
- Subject with an infection that requires parenteral antibiotic administration within 30 days prior to screening
- Subject who participated in another clinical trial within 6 months prior to the screening of this clinical trial
- Subject who was administered with immunosuppressants such as cyclosporin A or azathioprine within 6 weeks prior to the screening
- Clinical findings consistent with active infection or crystal disease in the index joint within 1 month prior to the screening
- History of fracture in the index limb or fracture with sequelae within 12 months prior to the screening
- Joint instability or history of acute dislocation within 12 months prior to the screening
- Planned or anticipated surgery of the joint during the study period
- Presence of surgical hardware or other foreign body in the index joint
- Surgery or arthroscopy of the index joint within 12 months of screening
- Treatment of the index joint with any investigational therapy within 6 months prior to the screening
- Known or suspected infection of the target joint
- Subject with reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease
- Subject with serious medical conditions other than cardiovascular disease
- Subject with, or with a medical history of autoimmune diseases
- Subject with a medical history of mental disorder or epilepsy
- Subject who was diagnosed with cancer within 5 years before screening
- Serious life-threatening conditions
- Allergies to anesthesia
- Subject who had intra-articular administration such as sodium hyaluronate injections within 6 months prior to the screening
- Intra-articular treatment of any joint with any of the following agents within 6 months prior to the screening: Any corticosteroid preparation (investigational or marketed), any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection)
- Subject abuse alcohol 10 times a week or smoke 25 cigarettes a day
- Subject who is breastfeeding
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 75 years old?
Where in United States
- Orthopedic & Sports Medicine Institute of Las VegasLas Vegas, United StatesContact: Randa Bascharon, DOTaking people
About the trial
What the trial wants to find out
This study is being conducted to evaluate the safety and tolerability of OA-SYS in patients with moderate to severe OA of the knee joint.
The group in the trial
- OA-SYSTreatment being tested
Treatment with OA-SYS
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open Label Phase IIb Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
- Plain-language title
- Safety of OA-SYS for moderate to severe knee osteoarthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06485843, who can take part
- Record updated
- 18 September 2025